Medical Information

EuroCARE IVF creates loving families by providing advanced fertility services to intended parents who are struggling with infertility.

euroCARE IVF, fertility clinic for Gender Selection CyprusPreimplantation genetic screening (PGS) for aneuploidy is a specialized genetic test that may be performed on embryos during IVF treatment in Cyprus.

Aneuploidy is the presence of an abnormal number of chromosomes in a cell (for example, a human cell having 45 or 47 chromosomes instead of the usual 46 or 23 pairs).

By carrying out PGS screening, euroCARE IVF offers a comprehensive analysis of all 24 sets of chromosomes including the two sex chromosomes (X and Y).  Therefore, during the PGS process we can also determine the gender of the embryos as well as ensuring the embryo is genetically healthy.  This advanced method of genetic screening assists our IVF experts in North Cyprus in choosing the best quality, healthy embryos to transfer of your desired gender.

PGS in North Cyprus is performed by implementing an embryo biopsy prior to transfer which identifies which embryos are chromosomally normal. Chromosomally normal embryos are the most likely to develop to term and to be born as a healthy baby.

The Treatment Process

A treatment cycle that includes PGS screening is carried out similarly to a standard IVF cycle. Initial testing is required in order for us to prepare your treatment plan. Day 1 of your menstrual cycle marks day 1 of the treatment process and stimulation injections begin on day 2.  A scan is required after 5 days of  injections and you are required to fly to Cyprus on day 9 of the process.  When your eggs are ready, they are collected by ultrasound-guided aspiration. Following our sperm sorting procedure, your eggs are then fertilized with your partners sperm (or donor sperm) by ICSI and the embryos are created.

On day 3 of embryo development they should have reached the 8 cell stage. At this time, one cell can then be safely removed. The embryos continue to divide and develop in the laboratory closely monitored by our experts.  The cell that has been removed undergoes the PGS screening — in which our laboratory can identify if there are any chromosomal anomalies and further learn the gender of the embryo.

On day 5 of the embryos development, your euroCARE IVF doctor will discuss with you the results of the PGS screening and help you decide which embryos to transfer. You can be confident that only good quality, genetically healthy embryos of your desired gender will be transferred.

Since the embryos must be transferred on day 5 then it is best to spend 11 days in Cyprus for the treatment.  If you wish to come to Cyprus for the full treatment then you would need to be here on day 1 of your period and stay for approx 20 days. You can have the necessary tests carried out here and go on to have the treatment in this time. The longer you can spend in Cyprus the better for the doctor to monitor you.

Accuracy of PGS Testing

You may ask how accurate is PGS testing? The PGS biopsy is 99.9% accurate in determining the gender of the embryos before they are returned to the womb.

Benefits of PGS in North Cyprus

Preimplantation Genetic Screening (PGS) allows you to choose the gender of your baby and to screen for numerical chromosomal abnormalities. Couples who are at increased risk for having aneuploidy embryos should consider using PGS testing at our euroCARE IVF Center. These groups of individuals include:

  • Women over 35 years of age
  • Couples who have experienced several spontaneous miscarriages of unknown cause
  • Couples with several cycles of IVF that have not achieved pregnancy
  • Men with low sperm concentration
  • Couples with a previous pregnancy with chromosomal abnormality
  • Couples who desire to choose the sex of their baby

Contact Us

Once you click the button you will receive your quote in your email within a few minutes and we will never spam you.

Resources:

Wikipedia Commons

Mayo Clinic

Live chat with patient coordinators

Please fill the form to start chatting with one of our patient coordinators.